Renibus Therapeutics to Present at Oppenheimer Private Life Sciences Showcase

SOUTHLAKE, Texas, Sept. 24, 2026 /CourierPR/ -- Renibus Therapeutics, a clinical-stage biopharmaceutical company focused on preventing and treating cardio, renal, and metabolic diseases, will participate in the Oppenheimer Private Life Sciences Company Showcase on September 29, 2026. The event will take place virtually, and Renibus will present its findings and plans.

Bhupinder Singh, MD, FASN, FNKF, Chief Medical Officer of Renibus, will deliver a virtual presentation at 11:15 am Eastern Standard Time. Company management will also conduct one-on-one meetings with investors during the conference. The showcase aims to provide a platform for private life sciences companies to present their latest developments and engage with potential investors.

Renibus Therapeutics is currently in Phase 3 development for its lead program, veverimer, which is intended for the treatment of metabolic acidosis in adults with chronic kidney disease. The company's second late-stage program, RBT-1, recently completed the PROTECT Phase 3 trial, which evaluated RBT-1 in patients undergoing cardiac surgery. The results suggest that further development in risk-enriched patient populations may be warranted, and the company is currently evaluating this direction.

RBT-1 has received both Breakthrough and Fast Track designations from the U.S. Food and Drug Administration (FDA), highlighting the potential significance of the program. Renibus Therapeutics continues to advance its research and development efforts, aiming to bring innovative treatments to patients suffering from various chronic conditions.

The company's participation in the Oppenheimer Private Life Sciences Company Showcase underscores its commitment to expanding its reach and engaging with the broader investment community. By presenting its latest findings and future plans, Renibus Therapeutics hopes to attract additional investment and support for its ongoing and upcoming clinical trials.